Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RTI-Pulmonary
- Development stage
- Unknown
- Lead developer
- Rejuvenation Technologies
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
RTI-Pulmonary (also known as TeloAT2) is an investigational mRNA-based therapy developed by Rejuvenation Technologies for the treatment of pulmonary fibrosis and chronic obstructive pulmonary disease (COPD). The therapy consists of modified mRNA encoding telomerase reverse transcriptase (TERT) encapsulated within lung-targeting lipid nanoparticles (LNPs). Upon intravenous administration, the LNPs deliver the mRNA to alveolar epithelial cells, where it is translated into functional TERT protein. This transiently activates the telomerase enzyme, leading to the extension of shortened telomeres. By reversing telomere attrition—a key driver of cellular senescence and tissue degeneration in idiopathic pulmonary fibrosis and familial telomere syndromes—the therapy aims to restore lung regenerative capacity and halt disease progression.
- Other names
- mRNA Telomerase Activator (pulmonary)mRNA-TERT-LNP
02
Targets
TERT (Telomerase)
Beyond the preview
Go deeper on RTI-Pulmonary.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RTI-Pulmonary.